
Annual report 2021
added 12-23-2023
Burning Rock Biotech Limited Market Cap 2011-2026 | BNR
As of March 24, 2026 Burning Rock Biotech Limited has a market cap of $ 230 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.95 B | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.95 B | 2.95 B | 2.95 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Lantheus Holdings
LNTH
|
5.12 B | $ 74.6 | -1.49 % | $ 5.03 B | ||
|
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M | ||
|
Bioventus
BVS
|
608 M | $ 9.28 | 3.11 % | $ 618 M | ||
|
Biodesix
BDSX
|
92.1 M | $ 15.5 | 5.51 % | $ 2.01 B | ||
|
Medpace Holdings
MEDP
|
13 B | $ 465.57 | 1.89 % | $ 13.4 B | ||
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | ||
|
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M | ||
|
Myriad Genetics
MYGN
|
409 M | $ 4.7 | 0.86 % | $ 435 M | ||
|
National Research Corporation
NRC
|
315 M | $ 17.38 | -0.77 % | $ 389 M | ||
|
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
34.9 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | ||
|
Pacific Biosciences of California
PACB
|
498 M | $ 1.39 | - | $ 417 M | ||
|
Charles River Laboratories International
CRL
|
7.69 B | $ 160.55 | 1.56 % | $ 7.96 B | ||
|
IQVIA Holdings
IQV
|
28.3 B | $ 168.36 | 0.81 % | $ 28.9 B | ||
|
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
7.95 M | $ 1.21 | -17.22 % | $ 6.59 M | ||
|
Mettler-Toledo International
MTD
|
28.4 B | $ 1 268.55 | 2.27 % | $ 26.1 B | ||
|
Interpace Biosciences
IDXG
|
4.12 M | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
Illumina
ILMN
|
16.4 B | $ 126.25 | 1.99 % | $ 20.1 B | ||
|
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B | ||
|
Precipio
PRPO
|
8.7 M | $ 27.01 | 0.3 % | $ 35.1 M | ||
|
Personalis
PSNL
|
254 M | $ 7.73 | 1.58 % | $ 458 M | ||
|
RadNet
RDNT
|
5.62 B | $ 59.61 | -3.45 % | $ 4.48 B | ||
|
Celcuity
CELC
|
399 M | $ 101.54 | -4.89 % | $ 4.01 B | ||
|
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 266.82 | 0.88 % | $ 22.2 B | ||
|
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | ||
|
Senseonics Holdings
SENS
|
351 M | $ 6.74 | 1.81 % | $ 281 M | ||
|
Sotera Health Company
SHC
|
4.75 B | $ 13.89 | 0.07 % | $ 3.94 B | ||
|
ENDRA Life Sciences
NDRA
|
2.2 M | $ 3.49 | 0.29 % | $ 1.87 M | ||
|
NeoGenomics
NEO
|
1.48 B | $ 7.94 | -1.98 % | $ 1.02 B | ||
|
Soleno Therapeutics
SLNO
|
2.08 B | $ 30.98 | -2.33 % | $ 1.57 B | ||
|
Natera
NTRA
|
5.31 B | $ 197.02 | -1.53 % | $ 19.4 B | ||
|
CareDx, Inc
CDNA
|
993 M | $ 17.95 | 2.22 % | $ 957 M | ||
|
Neuronetics
STIM
|
81.1 M | $ 1.49 | -6.88 % | $ 98.3 M | ||
|
OPKO Health
OPK
|
1.21 B | $ 1.14 | -1.3 % | $ 791 M | ||
|
Castle Biosciences
CSTL
|
709 M | $ 25.59 | -0.62 % | $ 711 M | ||
|
DarioHealth Corp.
DRIO
|
32.8 M | $ 7.99 | 6.53 % | $ 31.8 M | ||
|
DexCom
DXCM
|
25.5 B | $ 66.84 | 1.36 % | $ 26.1 B | ||
|
Exact Sciences Corporation
EXAS
|
19.5 B | $ 104.91 | - | $ 19.8 B |